Indirect effects of cytomegalovirus infection in solid organ transplant recipients

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue 1, 2008, Pages 38-47

  Pérez Sola, María José ^a   Castón, Juan José ^a   Solana, Rafael ^a   Rivero, Antonio ^a   Torre Cisneros, Julián ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Human cytomegalovirus; Indirect effects; Solid organ transplantation

Indexed keywords

ANTIVIRUS AGENT; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ACUTE GRAFT REJECTION; ANTIBODY PRODUCTION; ARTERY THROMBOSIS; BILE DUCT DISEASE; BRONCHIOLITIS OBLITERANS; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; CHRONIC GRAFT REJECTION; CHRONIC KIDNEY DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DIABETES MELLITUS; DISEASE SEVERITY; GRAFT RECIPIENT; GUILLAIN BARRE SYNDROME; HEPATITIS C; HUMAN; IMMUNE RESPONSE; INCIDENCE; INFECTION PREVENTION; NATURAL KILLER CELL; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; POLYMORPHONUCLEAR CELL; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIMARY INFECTION; RECURRENT INFECTION; REINFECTION; REVIEW; SUPERINFECTION; SURVIVAL RATE; VIREMIA; VIRUS REPLICATION;

EID: 38549143580     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13114394     Document Type: Review

References (88)

1. Fishman JA, Emery V, Freeman R, Pascual M, Rostaing L, Schlitt HJ, et al. Cytomegalovirus in transplantation. Challenging the status quo. Clin Transplant. 2007;21:149-58.
2. Franco A, Jiménez L, Aranda I, Álvarez L, González M, Rocamora N, et al. Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center. Nefrología. 2002;22:463-9.
3. Hodson E, Jones C, Webster A, Strippoli G, Barclay P, Kable K, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomised controlled trials. Lancet. 2005;365:2105-15.
4. Rowshani A, Bemelman F, Leeuwen E, Lier R, Berge I. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation. 2005;79:381-6.
5. Rubin R [editorial]. Prevention of cytomegalovirus infection in organ transplant recipients. Transpl Infect Dis. 2000;2:99-100.
6. Ljungman P. β-Herpesvirus challenges in the transplant recipient. J Infect Dis. 2002;186 Suppl 1:S99-109.
7. George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, et al. The Boston Center for Liver Transplantation CMVIG-Study Group. The independent role of CMV as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med. 1997;103:106-13.
8. Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J Clin Virol. 2006;35:474-7.
9. El-Sabrout R, Radovancevic B, Ankoma-Sey V, Buren C. Guillain- Barré syndrome after solid organ transplantation. transplantation. 2001;71:1311-6.
10. Smith R. CMV prophylaxis: a useful step towards prevention of post-transplant diabetes? Diabetologia. 2004;47:1473-5.
11. Pérez Sáenz JL, Cisneros-Herreros JM. Infecciones por citomegalovirus. En: Auxina Ruiz V, Moreno Guillén S, editores. Tratado SEIMC de Enfermedades Infecciosas y Microbiología Clínica. Buenos Aires: Editorial Médica Panamericana; 2006. p. 747-57.
12. Pass RF. Cytomegalovirus. En: Knipe DM, Howley PM, Griffin DE, Lamb RA, editors. Fields virology. Philadelphia: Lippincott, Williams & Wilkins; 2001. p. 2675-705.
13. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999;17:189-220.
14. Yokoyama WM, Scalzo AA. Natural killer cell activation receptors in innate immunity to infection. Microbes Infect. 2002;4:1513-21.
15. Gamadia LE, Rentenaar RJ, Baars PA, Remmerswaal EB, Surachno S, Weel JF, et al. Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers. Blood. 2001;98:754-61.
16. Moss P, Khan N. CD8(+) T-cell immunity to cytomegalovirus. Hum Immunol. 2004;65:456-64.
17. Hengel H, Brune W, Koszinowski UH. Immune evasion by cytomegalovirus - Survival strategies of a highly adapted opportunist. Trends Microbiol. 1998;6:190-7.
18. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. Viral subversion of the immune system. Annu Rev Immunol. 2000;18:861-926.
19. Reddehase MJ. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol. 2002;2:831-44.
20. Borrego F, Kabat J, Kim DK, Lieto L, Maasho K, Pena J, et al. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol. 2002;38:637-60.
21. López-Botet M, Angulo A, Gumá M. Natural killer cell receptors for major histocompatibility complex class I and related molecules in cytomegalovirus infection. Tissue Antigens. 2004;63:195-203.
22. Welte SA, Sinzger C, Lutz SZ, Singh-Jasuja H, Sampaio KL, Eknigk U, et al. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol. 2003;33:194-203.
23. Tomasec P, Wang EC, Davison AJ, Vojtesek B, Armstrong M, Griffin C, et al. Downregulation of natural killer cell activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol. 2005;6:181-8.
24. Chapman TL, Heikeman AP, Björkman PJ. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity. 1999;11:603-13.
25. Wang EC, McSharry B, Retiere C, Tomasec P, Williams S, Borysiewicz LK, et al. UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proc Natl Acad Sci U S A. 2002;99:7570-5.
26. Simon CO, Holtappels R, Tervo HM, Bohm V, Daubner T, Oehrlein-Karpi SA, et al. CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol. 2006;80:1043-56.
27. Koch S, Solana R, DelaRosa O, Pawelec G. Human cytomegalovirus infection and T cell immunosenescence: a mini review. Mech Ageing Dev. 2006;127:538-43.
28. Pawelec G, Akbar A, Caruso C, Solana R, Grubeck-Loebenstein B, Wikby A. Human immunosenescence: is it infectious? Immunol Rev. 2005;205:257-68.
29. DelaRosa O, Pawelec G, Peralbo E, Wikby A, Mariani E, Mocchegiani E, et al. Immunological biomarkers of ageing in man: changes in both innate and adaptive immunity are associated with health and longevity. Biogerontology. 2006;7:471-81.
30. Solana R, Pawelec G, Tarazona R. Aging and innate immunity. Immunity. 2006;24:491-4.
31. Addo MM, Rosenberg ES. Cellular immune responses in transplantation- associated chronic viral infections. Transpl Infect Dis. 2002;4:31-40.
32. Mañez R, Breining MC, Linden P, Wilson J, Torre-Cisneros J, Kusne S, et al. Post-transplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis. 1997;176:1462-7.
33. Pozo F, Tenorio A, de la Mata M, de Ory F, Torre-Cisneros J. Persistent human herpesvirus 8 viremia before Kaposi's sarcoma development in a liver transplant recipient. Transplantation. 2000;70:395-7.
34. Pahissa Berga A, Gavaldá Santapau J. Infecciones en el paciente sometido a un trasplante de órgano sólido. En: Auxina Ruiz V, Moreno Guillén S, editores. Tratado SEIMC de Enfermedades Infecciosas y Microbiología Clínica. Buenos Aires: Editorial Médica Panamericana; 2006. p. 1467-85.
35. Pereyra F, Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis. 2004;17:357-61.
36. Nordøy I, Müller F, Nordal KP, Rollag H, Lien E, Aukrust P, et al. The role of the tumor necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients. J Infect Dis. 2000;181:51-7.
37. Durandy A. Anti-B cell and anti-cytokine therapy for the treatment of post-transplant lymphoproliferative disorder: past, present, and future. Transpl Infect Dis. 2001;3:104-7.
38. Wreghitt T. Cytomegalovirus infections in heart and heart-lung transplant recipients. J Antimicrob Chemother. 1989;23 Suppl E:49-60.
39. Westall G, Michaelides A, Williams T, Snell G, Kotsimbos T. Bronchiolitis obliterans syndrome and early human cytomegalovirus dnaemia dynamics after lung transplantation. Transplantation. 2003;75:2064-8.
40. Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant. 2002;21:271-81.
41. Cerrina J, Le Roy Ladurie F, Herve PH, Parquin F, Harari S, Chapelier A, et al. Role of CMV pneumonia in the development of obliterative bronchiolitis in heart-lung and double-lung transplant recipient. Transpl Int. 1992;5 Suppl 1:S242-5.
42. Nett P, Hesey D, Fernandez L, Sollinger H, Pirsch J. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation. 2004;78:1036-41.
43. McLaughlin K, Wu K, Fick G, Muirhead N, Hollomby D, Jevnikar A. Cytomegalovirus seromismatching increases the risk of acute renal allograft rejection. Transplantation. 2002;74:813-6.
44. Malaise J, Ricart MJ, Moreno A, Crespo M, Fernández-Cruz L, Van Ophen D, et al. Cytomegalovirus infection in simultaneous pancreas-kidney transplantation. Transplant Proc. 2005;37:2848-50.
45. Ricart MJ, Malaise J, Moreno A, Crespo M, Fernández-Cruz L. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant. 2005;20 Suppl 1:3-7.
46. Lopez-Rocafort L, Brennan DC. Current review of cytomegalovirus in renal transplantation. Minerva Urol Nefrol. 2001;53:145-58.
47. Kalil R, Hudson S, Gaston R. Determinants of cardiovascular mortality after renal transplantation: a role for cytomegalovirus? Am J Transplant. 2003;3:79-81.
48. Oña M, Melón S, Álvarez M, Laures A, Boga J, González D, et al. Relación de la replicación del CMV y el riesgo de enfermedad cardiovascular en el trasplante renal. Capítulo 501. Sesión 24. Infecciones en el inmunodeprimido no VIH. Enferm Infecc Microbiol Clin. 2004;22:175-82.
49. Helantera I, Koskinen P, Tornroth T, Loginov R, Gronhagen-Riska C, Lautenschlarger I. The impact of cytomegalovirus infections and acute rejection episodes on the development of vascular changes in 6-month protocol biopsy specimens of cadaveric kidney allograft recipients. Transplantation. 2003;75:1858-64.
50. Söderberg-Nauclér C, Emery VC. Viral infections and their impact on chronic renal allograft dysfunction. Transplantation. 2001;71 Suppl 11:SS24-30.
51. Sagedal S, Hartmann A, Nordal K, Osnes K, Leivestad T, Foss A. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int. 2004;66:329-37.
52. Dickenmann M, Cathomas G, Steiger J, Mihatsch M, Thiel G, Tamm M. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation. 2001;71:764-7.
53. Fuchs U, Zittermann A, Tenderich G, Minami K, Koerfer R. Cytomegalovirus-induced pancytopenia after heart transplantation. Transplantation. 2004;78:783-4.
54. Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med. 1996;335:624-30.
55. Hosenpud JD. Coronary artery disease after heart transplantation and its relation to cytomegalovirus. Am Heart J. 1999;138 (5 Pt 2):S469-72.
56. Eryol NK, Kiliç H, Gül A, Özdogru I, Inanç T, Dogan A, et al. Are the high levels of cytomegalovirus antibodies a determinant in the development of coronary artery disease? Int Heart J. 2005;46:205-9.
57. Fateh-Moghadam S, Bocksch W, Wessely R, Jager G, Hetzer R, Gawaz M. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation. 2003;76:1470-4.
58. Weill D. Role of cytomegalovirus in cardiac allograft vasculopathy. Transpl Infect Dis. 2001;3 Suppl 2:44-8.
59. Valantine H. The role of viruses in cardiac allograft vasculopathy. Am J Transplant. 2003;4:169-77.
60. Streblow DN, Orloff SL, Nelson JA. The HCMV chemokine receptor US28 is a potential target in vascular disease. Curr Drug Targets Infect Disord. 2001;1:151-8.
61. Van Dam-Mieras MC, Muller AD, Van Hinsbergh VW, Mullers WJ, Bomans PH, Bruggeman CA. The procoagulant response of cytomegalovirus infected endothelial cells. Thromb Haemost. 1992;68:364.
62. Petrakopoulou P, Kübrich M, Pehlivanli S, Meiser B, Reichar B, von Scheidt W, et al. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation. 2004;110 (11 Suppl II):II207-12.
63. Potena L, Grigioni F, Ortolani P, Magnani G, Marrozzini C, Falchetti E, et al. Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. Transplantation. 2003;75:839-43.
64. Gao LH, Zheng SS. Cytomegalovirus and chronic allograft rejection in liver transplantation. World J Gastroenterol. 2004;10:1857-61.
65. Burak K, Kremers W, Batts K, Wiesner R, Rosen C, Razonable R, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl. 2002;8:362-9.
66. Halme L, Höckerstedt K, Lautenschlager I. Cytomegalovirus infection and development of biliary complications after liver transplantation. Transplantation. 2003;75:1853-8.
67. Madalosso C, De Souza NF, Ilstrup DM, Wiesner RH, Krom RAF. Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation. Transplantation. 1998;66:294-7.
68. Razonable R, Burak K, Van Cruijsen H, Brown R, Charlton M, Smith T, et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis. 2002;35:974-81.
69. Otero J, Gavaldà J, Murio E, Vargas V, Calicó I, Llopart L, et al. Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis. 1998;26:865-70.
70. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol. 2005;42:448-56.
71. Berenguer M, López-Labrador FX, Wrigth TL. Hepatitis C and liver transplantation. J Hepatol. 2001;35:666-78.
72. Berenguer M. Host and donor pre- and post-liver transplant risk factors impacting on HCV recurrence. Liver Transpl. 2003;9:S44-S7.
73. Rosen HR, Chou S, Corless CL, Gretch DR, Flora KD, Boudousquie A, et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation. 1997;64:721-6.
74. Humar A, Kumar D, Raboud J, Caliendo AM, Moussa G, Levy G, et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant. 2002;2:461-6.
75. Slifkin M, Ruthazer R, Freeman R, Blomm J, Fitzmaurice S, Fairchild R, et al. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Liver Transpl. 2005;11:1597-602.
76. Fortún J, Martín-Dávila P, Moreno S, De Vicente E, Nuno J, Candelas A, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl. 2002;8:1065-70.
77. Sagedal S, Nordal KP, Hartmann A, Midtvedt K, Foss A, Asberg A, et al. Pre-emptive therapy of CMV pp65 antigen positive renal transplant recipients with oral ganciclovir; a randomized, comparative study. Nephrol Dial Transplant. 2003;18:1899-908.
78. Singh N, Wannstedt C, Keyes L, Wagener MM, Gayowski T, Cacciarelli TV, et al. Indirect effects associated with CMV (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver transplant recipients with the use of pre-emptive therapy for 13 years. Transplantation. 2005;79:1428-34.
79. Torre-Cisneros J, Fortún J, Aguado JM, Cámara R, Cisneros JM, Gavaldà J, et al. Recomendaciones GESITRA-SEIMC y RESITRA sobre prevención y tratamiento de la infección por citomegalovirus en pacientes trasplantados. Enferm Infecc Microbiol Clin. 2005;23:424-37.
80. Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus in adult renal transplant recipients. Am J Transplant. 2006;6:2134-43.
81. Kalil AC, Levitsky J, Lyden E, Stoner J, Lesiak B, Bargenquast K, et al. Pre-emptive therapy and universal prophylaxis for cytomegalovirus in solid organ transplant recipients: a meta-analyses. 4th Annual Meeting of IDSA. 2004:167 (abs. 639).
82. Snydman DR. Counterpoint: prevention of cytomegalovirus infection and cmv disease in recipients of solid organ transplants: the case for prophylaxis. Clin Infect Dis. 2005;40:709-12.
83. Briceño J, Torre-Cisneros J, Sánchez-Guijo P, Pera-Madrazo C. Cyclosporine and anti-cd3 blockade of lymphocyte apoptosis induced by cytomegalovirus antigens. Transplant Proc. 1999;31:1370.
84. Moreno J, Montero JL, Gavilán F, Costán G, Herrero C, Cárdenas M, et al. Ensayo clínico abierto con aciclovir oral para la profilaxis de la enfermedad por citomegalovirus en receptores de un trasplante hepático de bajo riesgo. Enferm Infecc Microbiol Clin. 1999;17:382-5.
85. Gavilán F, Caballero J, Cárdenas M, Moreno J, Martínez L, Gallego C, et al. El aciclovir puede modular la expansión clonal de linfocitos CD8+ inducida por antígeno de citomegalovirus. Enferm Infecc Microbiol Clin. 1999;17:390-3.
86. Lowance D, Neumayer HH, Legendie CM, Squifflet JP, Kovarik J, Brennan PJ, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med. 1999;340:1462-70.
87. Opelz G, Döhler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:928-36.
88. Strippoli GFM, Hodson EM, Jones C, Craig JC. Pre-emptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation. 2006;81:139-45.